Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.
atrial fibrillation
ejection fraction
heart failure
mortality
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
13 Feb 2024
13 Feb 2024
Historique:
revised:
03
01
2024
received:
16
10
2023
accepted:
28
01
2024
medline:
13
2
2024
pubmed:
13
2
2024
entrez:
13
2
2024
Statut:
aheadofprint
Résumé
Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). Aggregate data comparing the risk profile of AF between these three HF categories are lacking. We conducted a systematic review and meta-analysis aimed at determining any significant differences in AF-associated all-cause mortality, HF hospitalizations, cardiovascular mortality (CV), and stroke between HFrEF, HFmrEF, and HFpEF. A systematic search of PubMed, EMBASE, and Cochrane Library databases until February 28, 2023. Data were combined using DerSimonian-Laird random effects model. A total of 22 studies comprising 248 323 patients were retained: HFrEF 123 331 (49.7%), HFmrEF 40 995 (16.5%), and HFpEF 83 997 (33.8%). Pooled baseline AF prevalence was 36% total population, 30% HFrEF, 36% HFmrEF, and 42% HFpEF. AF was associated with a higher risk of all-cause mortality in the total population with pooled hazard ratio (HR) = 1.13 (95% confidence interval [CI] = 1.07-1.21), HFmrEF (HR = 1.25, 95% CI = 1.05-1.50) and HFpEF (HR = 1.16, 95% CI = 1.09-1.24), but not HFrEF (HR = 1.03, 95% CI = 0.93-1.14). AF was associated with a higher risk of HF hospitalizations in the total population (HR = 1.29, 95% CI = 1.14-1.46), HFmrEF (HR = 1.64, 95% CI = 1.20-2.24), and HFpEF (HR = 1.46, 95% CI = 1.17-1.83), but not HFrEF (HR = 1.01, 95% CI = 0.87-1.18). AF was only associated with CV in the HFpEF subcategory but was associated with stroke in all three HF subtypes. AF appears to be associated with a higher risk of all-cause mortality and HF hospitalization in HFmrEF and HFpEF. With these findings, the paucity of data and treatment guidelines on AF in the HFmrEF subgroup becomes even more significant and warrant further investigations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. The Lancet. 2020;396(10258):1204-1222.
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020;141(9):e139-e596.
Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction. J Am Coll Cardiol. 2017;70(20):2476-86.
Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-1402.
Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure society of america, heart failure association of the european society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association. Eur J Heart Fail. 2021;23(3):352-380.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032.
O'Neal WT, Qureshi W, Zhang ZM, Soliman EZ. Bidirectional association between atrial fibrillation and congestive heart failure in the elderly. J Cardiovasc Med. 2016;17(3):181-186.
Andersson T, Magnuson A, Bryngelsson IL, et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int J Cardiol. 2014;177(1):91-99.
Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011;123(15):1587-1593.
O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761-775.
Odutayo A, Wong CX, Williams R, Hunn B, Emdin CA. Prognostic importance of atrial fibrillation timing and pattern in adults with congestive heart failure: a systematic review and meta-analysis. J Card Failure. 2017;23(1):56-62.
Naka KK, Bazoukis G, Bechlioulis A, Korantzopoulos P, Michalis LK, Ntzani EE. Association between atrial fibrillation and patient-important outcomes in heart failure patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis. Euro Heart J. 2019;5(2):96-104.
Liu G, Long M, Hu X, Hu CH, Du ZM. Meta-Analysis of atrial fibrillation and outcomes in patients with heart failure and preserved ejection fraction. Heart, Lung Circ. 2021;30(5):698-706.
Pellicori P, Urbinati A, Kaur K, et al. Prevalence and incidence of atrial fibrillation in ambulatory patients with heart failure. Am J Cardiol. 2019;124(10):1554-60.
Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133(5):484-492.
Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC: Heart Failure. 2017;5(8):565-574.
Satish M, Guddeti R, Wenzl F, Walters R, Alla VM Abstract 12813: atrial fibrillation and heart failure with preserved ejection fraction: a systematic review and meta-analysis. Circulation. 2020;142(suppl 3):A12813-A.
Nicoli CD, O'Neal WT, Levitan EB, et al. Atrial fibrillation and risk of incident heart failure with reduced versus preserved ejection fraction. Heart. 2022;108(5):353-359.
Vermond RA, Geelhoed B, Verweij N, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality. J Am Coll Cardiol. 2015;66(9):1000-1007.
Pandey A, Kim S, Moore C, et al. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC: Heart Failure. 2017;5(1):44-52.
Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
Mundisugih J, Franke KB, Tully PJ, Munawar DA, Kumar S, Mahajan R. Prevalence and prognostic implication of atrial fibrillation in heart failure subtypes: systematic review and meta-analysis. Heart Lung Circ. 2023;32:666-667.
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021.
Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991-996.
Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A. Clinical characteristics and prognosis of patients admitted for heart failure: a 5-year retrospective study of African patients. Int J Cardiol. 2017;238:128-135.
Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721-730.
Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574-1585.
Cho JH, Choe WS, Cho HJ, et al. Comparison of characteristics and 3-year outcomes in patients with acute heart failure with preserved, mid-range, and reduced ejection fraction. Circ J. 2019;83(2):347-356.
Dzudie A, Hongieh Abanda M, Nkoke C, et al. Clinical characteristics and outcomes of black African heart failure patients with preserved, mid-range, and reduced ejection fraction: a post hoc analysis of the THESUS-HF registry. ESC Heart Failure. 2021;8(1):238-249.
Escobar C, Palacios B, Varela L, et al. Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. J Clin Med. 2022;11(17):5199.
Farmakis D, Simitsis P, Bistola V, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol. 2017;106(5):359-368.
Gómez-Otero I, Ferrero-Gregori A, Varela Román A, et al. La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca. Rev Esp Cardiol. 2017;70(5):338-346.
Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas Ó, et al. Heart failure with mid-range ejection fraction in patients admitted to internal Medicine departments: findings from the RICA registry. Int J Cardiol. 2018;255:124-128.
Hao C, Luo J, Liu B, et al. Prognostic significance of New-Onset atrial fibrillation in heart failure with preserved, Mid-Range, and reduced ejection fraction following acute myocardial infarction: data from the NOAFCAMI-SH registry. Clin Interv Aging. 2022;17:479-493.
Kapłon-Cieślicka A, Benson L, Chioncel O, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction-insights from the ESC-HFA EORP heart failure Long-Term registry. Eur J Heart Fail. 2022;24(2):335-350.
Lund LH, Benson L, Dahlström U, Edner M, Friberg L. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014;312(19):2008-2018.
Miró Ò, Conde-Martel A, Llorens P, et al. The influence of comorbidities on the prognosis after an acute heart failure decompensation and differences according to ejection fraction: results from the EAHFE and RICA registries. Eur J Intern Med. 2023;111:97-104.
Nji MAM, Solomon SD, Chen LY, et al. Association of heart failure subtypes and atrial fibrillation: data from the atherosclerosis risk in communities (ARIC) study. Int J Cardiol. 2021;339:47-53.
Rywik TM, Doryńska A, Wiśniewska A. Epidemiology and clinical characteristics of hospitalized patients with heart failure with reduced, mildly reduced, and preserved ejection fraction. Pol Arch Med Wewn. 2022;132:5.
Shiga T, Suzuki A, Haruta S, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. ESC Heart Failure. 2019;6(3):475-486.
Savarese G, Settergren C, Schrage B, et al. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design. Int J Cardiol. 2020;313:76-82.
Son MK, Park JJ, Lim NK, Kim WH, Choi DJ. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction. Heart. 2020;106(15):1160-1168.
Xu HX, Zhu YM, Hua Y, Huang YH, Lu Q. Association between atrial fibrillation and heart failure with different ejection fraction categories and its influence on outcomes. Acta Cardiol. 2020;75(5):423-432.
Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the european society of cardiology heart failure long-term registry. Eur Heart J. 2018;39(48):4277-4284.
Chen S, Huang Z, Liang Y, et al. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort. ESC. Heart Fail. 2022;9(4):2336-2347.
Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GYH. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660-666.
Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D. The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis. Eur J Heart Fail. 2014;16(12):1317-1322.
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-427.
AlTurki A, Proietti R, Dawas A, Alturki H, Huynh T, Essebag V. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2019;19(1):18.
Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11(7):676-683.
Uhm JS, Kim J, Yu HT, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. ESC Heart Fail. 2021;8(2):1582-1589.
Gopinathannair R, Chen LY, Chung MK, et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American heart association. Circu Arrhyth Electroph. 2021;14(7):e000078.
Patil S, Shah M, Patel B, Agarwal M, Ram P, Alla VM. Readmissions among patients admitted with acute decompensated heart failure based on income quartiles. Mayo Clin Proc. 2019;94(10):1939-1950.
Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-day readmission rates for heart failure. Circ Heart Fail. 2021;14(4):e008335.
Gupta A, Allen LA, Bhatt DL, et al. Association of the hospital readmissions reduction program implementation with readmission and mortality outcomes in heart failure. JAMA Cardiol. 2018;3(1):44-53.
Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100-116.
Reinhardt SW, Chouairi F, Miller PE, et al. National trends in the burden of atrial fibrillation during hospital admissions for heart failure. J Am Heart Assoc. 2021;10(11):e019412.
Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation. 2020;141(1):4-6.
Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119(18):2516-2525.
Yang E, Vaishnav J, Song E, et al. Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction. ESC Heart Failure. 2022;9(5):2918-2927.
Saglietto A, De Ponti R, Di Biase L, et al. Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: a meta-analysis. J Cardiovasc Electrophysiol. 2020;31(5):1040-1047.
Ravi V, Poudyal A, Lin L, et al. Mortality benefit of catheter ablation versus medical therapy in atrial fibrillation: an RCT only meta-analysis. J Cardiovasc Electrophysiol. 2022;33(2):178-193.
Rattka M, Kühberger A, Pott A, et al. Catheter ablation for atrial fibrillation in HFpEF patients-A propensity-score-matched analysis. J Cardiovasc Electrophysiol. 2021;32(9):2357-2367.
Androulakis E, Sohrabi C, Briasoulis A, et al. Catheter ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. J Clin Med. 2022;11(2):288
Aldaas OM, Lupercio F, Darden D, et al. Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2021;142:66-73.
Siddiqui MU, Junarta J, Riley JM, et al. Catheter ablation in patients with atrial fibrillation and heart failure with preserved ejection fraction: a systematic review and meta-analysis. J Arrhythm. 2022;38(6):981-990.
Mekhael M, Shan B, Noujaim C, et al. Catheter ablation improved ejection fraction in persistent AF patients: a DECAAF-II sub analysis. EP Europace. 2023;25(3):889-895.